Literature DB >> 34717148

DOG1 expression is common in human tumors: A tissue microarray study on more than 15,000 tissue samples.

Kristina Jansen1, Nagina Farahi1, Franziska Büscheck1, Maximilian Lennartz1, Andreas M Luebke1, Eike Burandt1, Anne Menz1, Martina Kluth1, Claudia Hube-Magg1, Andrea Hinsch1, Doris Höflmayer1, Sören Weidemann1, Christoph Fraune1, Katharina Möller1, Patrick Lebok1, Guido Sauter1, Ronald Simon2, Ria Uhlig1, Waldemar Wilczak1, Frank Jacobsen1, Sarah Minner1, Rainer Krech3, Till Clauditz1, Christian Bernreuther1, David Dum1, Till Krech4, Andreas Marx5, Stefan Steurer1.   

Abstract

DOG1 (Discovered on GIST1) is a voltage-gated calcium-activated chloride and bicarbonate channel that is highly expressed in interstitial cells of Cajal and in gastrointestinal stromal tumors (GIST) derived from Cajal cells. To systematically determine in what tumor entities and normal tissue types DOG1 may be further expressed, a tissue microarray (TMA) containing 15,965 samples from 121 different tumor types and subtypes as well as 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry. DOG1 immunostaining was found in 67 tumor types including GIST (95.7%), esophageal squamous cell carcinoma (31.9%), pancreatic ductal adenocarcinoma (33.6%), adenocarcinoma of the Papilla Vateri (20%), squamous cell carcinoma of the vulva (15.8%) and the oral cavity (15.3%), mucinous ovarian cancer (15.3%), esophageal adenocarcinoma (12.5%), endometrioid endometrial cancer (12.1%), neuroendocrine carcinoma of the colon (11.1%) and diffuse gastric adenocarcinoma (11%). Low level-DOG1 immunostaining was seen in 17 additional tumor entities. DOG1 expression was unrelated to histopathological parameters of tumor aggressiveness and/or patient prognosis in cancers of the breast (n = 1002), urinary bladder (975), ovary (469), endometrium (173), stomach (233), and thyroid gland (512). High DOG1 expression was linked to estrogen receptor expression in breast cancer (p < 0.0001) and absence of HPV infection in squamous cell carcinomas (p = 0.0008). In conclusion, our data identify several tumor entities that can show DOG1 expression levels at similar levels as in GIST. Although DOG1 is tightly linked to a diagnosis of GIST in spindle cell tumors, the differential diagnosis is much broader in DOG1 positive epithelioid neoplasms.
Copyright © 2021 The Authors. Published by Elsevier GmbH.. All rights reserved.

Entities:  

Keywords:  DOG1; immunohistochemistry; tissue micro array, human cancer

Mesh:

Substances:

Year:  2021        PMID: 34717148     DOI: 10.1016/j.prp.2021.153663

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  3 in total

1.  DOG1 overexpression is associated with mismatch repair deficiency and BRAF mutations but unrelated to cancer progression in colorectal cancer.

Authors:  Kristina Jansen; Martina Kluth; Niclas C Blessin; Claudia Hube-Magg; Michael Neipp; Hamid Mofid; Hannes Lárusson; Thies Daniels; Christoph Isbert; Stephan Coerper; Daniel Ditterich; Holger Rupprecht; Albert Goetz; Christian Bernreuther; Guido Sauter; Ria Uhlig; Waldemar Wilczak; Ronald Simon; Stefan Steurer; Eike Burandt; Daniel Perez; Jakob R Izbicki; Frank Jacobsen; Till S Clauditz; Andreas H Marx; Till Krech
Journal:  Histol Histopathol       Date:  2022-06-01       Impact factor: 2.130

2.  Overexpression of zinc-finger protein 677 inhibits proliferation and invasion by and induces apoptosis in clear cell renal cell carcinoma.

Authors:  W Liang; Sh Chen; Gl Yang; Jy Feng; Q Ling; B Wu; Hb Yan; Jw Cheng
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

3.  Semi-automated validation and quantification of CTLA-4 in 90 different tumor entities using multiple antibodies and artificial intelligence.

Authors:  David Dum; Tjark L C Henke; Tim Mandelkow; Cheng Yang; Elena Bady; Jonas B Raedler; Ronald Simon; Guido Sauter; Maximilian Lennartz; Franziska Büscheck; Andreas M Luebke; Anne Menz; Andrea Hinsch; Doris Höflmayer; Sören Weidemann; Christoph Fraune; Katharina Möller; Patrick Lebok; Ria Uhlig; Christian Bernreuther; Frank Jacobsen; Till S Clauditz; Waldemar Wilczak; Sarah Minner; Eike Burandt; Stefan Steurer; Niclas C Blessin
Journal:  Lab Invest       Date:  2022-01-29       Impact factor: 5.502

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.